Marcelle G. Cesca

Agulha, SP, Brazil

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Journal: JCO oncology practice
Published: March 06, 2026

Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Journal: JCO global oncology
Published: January 30, 2026

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.

Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.

Journal: Breast cancer research and treatment
Published: August 11, 2025

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Journal: Breast (Edinburgh, Scotland)
Published: May 04, 2025

Loss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer.

Loss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer.

Journal: Ecancermedicalscience
Published: September 20, 2023

Influence of proton pump inhibitors on the pathological response of rectal cancer: a multicentre study.

Influence of proton pump inhibitors on the pathological response of rectal cancer: a multicentre study.

Journal: Ecancermedicalscience
Published: January 09, 2023

Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients.

Distinct systemic immune networks define severe vs. mild COVID-19 in hematologic and solid cancer patients.

Journal: Frontiers in immunology
Published: September 23, 2022

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Journal: Therapeutic advances in medical oncology
Published: September 21, 2022

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.

HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.

Journal: Breast cancer research and treatment
Published: April 17, 2021

HER2-positive advanced breast cancer treatment in 2020.

HER2-positive advanced breast cancer treatment in 2020.

Journal: Cancer treatment reviews
Published: April 07, 2020

Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.

Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.

Journal: BMC cancer
Published: March 14, 2019

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.

Journal: British journal of cancer
Published: June 21, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026